Key facts
- Qureator’s last known valuation is $136.7M (Mar 2026).
- It has raised $36.7M across 1 recorded rounds; the latest was Early Stage VC ($6.7M) in Dec 2025.
- Notable investors include Tech Incubator Program for Startup, STIC Ventures, Seoul National University Technology Holdings, HG Initiative, K-Bridge Investment — 8 tracked in total.
- Qureator has filed 1 Form D with the SEC, most recently Mar 2026 ($6.7M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Qureator
Funding rounds
1 roundsAbout Qureator
Developer of biotechnology research platforms intended to create human-relevant disease models for drug discovery. The company offers organ-on-a-chip platforms, microphysiological systems, 3D cell culture models, AI-based biological analysis, and commissioned research services, enabling pharmaceutical and biotechnology researchers access to tools for studying disease mechanisms and evaluating drug candidates.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 26
- Website
- qureator.com/
- Ownership
- Privately Held (backing)
Qureator doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qureator shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qureator in its N-PORT filings yet. We sweep new filings monthly.